FindTrial
Sign In

Use of Modified frailty Index (mFi) for prediction of postoperative complications in patients undergoing Cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy

Utility of Modified frailty Index (mFi) for predicting postoperative complications after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/05/033669
Enrollment
300
Registered
2021-05-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C260- Malignant neoplasm of intestinal tract, part unspecified

Interventions

Control Intervention1: Nil: Nil Control Intervention2: Nil: Nil

Sponsors

Dr Malini Joshi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients above 18 years who underwent Cytoreductive surgeries with Hyperthermic Intraperitoneal Chemotherapy under general anesthesia

Exclusion criteria

Exclusion criteria: Paediatric patients

Design outcomes

Primary

MeasureTime frame
Major post operative complications (clavien dindo class 3-4) within 30 post operative daysTimepoint: Date of surgery to 30 days post operative period—

Secondary

MeasureTime frame
1. Mortality 2. Need for vasopressin 3. Need and duration of postop ventilation 4. Any other organ support 5. ICU length of stay 6. Hospital length of stay 7. Hospital outcomeTimepoint: Date of surgery to 30 days postoperative period—

Countries

India

Contacts

Public ContactDr Malini Joshi

Tata memorial hospital

jmalini2007@rediffmail.com9987226657

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026